A factory that fills American medicine cabinets
Few Americans have heard of the F.T.O. U-3 factory in Hyderabad, yet its products reach millions of homes. Around 1,900 workers at the Dr. Reddy's Laboratories plant produce more than 100 generic medicines around the clock, including antihistamines, statins, beta blockers and antidepressants.
Of the nearly one billion oral doses made there each month, about 75% are shipped to patients in the United States. This scale has turned India into a cornerstone of the global drug supply, particularly in the high-volume, low-margin world of generics.
It is precisely this scale that makes the Trump administration's goal so daunting: replacing India's output would require not just new factories but a fundamentally different cost structure.
Tariffs as a lever
Trump has made clear he intends to use tariffs to pressure drugmakers into producing in the United States, though his approach to generics has so far been cautious.
- In a July social media post, he said he planned a 100% tariff on generic drugs from 2028 and a 200% tariff a year later, after his term ends.
















